Literature DB >> 10621922

Comparison of the efficacy and safety of a new aluminium-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux.

S Miller.   

Abstract

The aim of the present study was to compare the efficacy and safety of a new aluminium-free formulation of alginate with placebo in infants with recurrent gastro-oesophageal reflux. This was a double-blind, randomised, parallel-group study conducted at 25 centres in the UK. Of the 90 paediatric patients recruited in a general practice setting, 42 were randomised to receive alginate and 48 to receive placebo. Infants were assessed before treatment and again after seven and 14 days of treatment. Analyses were based on the last, valid, non-missing observation for each variable for the intent-to-treat (ITT) population of 42 alginate and 46 placebo patients. For the primary efficacy measure (number of vomitting/regurgitation episodes), alginate was significantly superior to placebo (p = 0.009). For the secondary efficacy measure (severity of vomiting), a trend in favour of alginate was observed (p = 0.061). Patients receiving alginate achieved superior assessments of treatment outcome by both investigators (p = 0.008) and parent/guardians (p = 0.002) alike. In addition, alginate achieved a significantly greater reduction in the mean severity of vomiting episodes recorded in a daily diary compared with placebo (p = 0.027) and resulted in more patients having at least 10% symptom-free days (p = 0.027). For none of the variables measured did placebo have a superior effect. More than one-half of all patients experienced some adverse event, although no statistically significant differences were observed between the two treatment groups (p > 0.1), and adverse events accounted for withdrawal in only 12.5% of the patients (alginate, n = 4; placebo, n = 7). Aluminium-free alginate demonstrated superior efficacy over placebo in treating recurrent gastro-oesophageal reflux in paediatric patients. The safety profile of alginate was similar to that of placebo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10621922     DOI: 10.1185/03007999909114087

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  10 in total

Review 1.  Optimizing the Use of Medications and Other Therapies in Infant Gastroesophageal Reflux.

Authors:  Steven L Ciciora; Frederick W Woodley
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 2.  Feed thickener for infants up to six months of age with gastro-oesophageal reflux.

Authors:  T'ng Chang Kwok; Shalini Ojha; Jon Dorling
Journal:  Cochrane Database Syst Rev       Date:  2017-12-05

3.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

Review 4.  GORD in children.

Authors:  Yadlapalli Kumar; Rajini Sarvananthan
Journal:  BMJ Clin Evid       Date:  2008-10-01

Review 5.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

Review 7.  Pharmacological treatment of children with gastro-oesophageal reflux.

Authors:  Mark Tighe; Nadeem A Afzal; Amanda Bevan; Andrew Hayen; Alasdair Munro; R Mark Beattie
Journal:  Cochrane Database Syst Rev       Date:  2014-11-24

8.  Pharmacological therapy of gastroesophageal reflux in preterm infants.

Authors:  Luigi Corvaglia; Caterina Monari; Silvia Martini; Arianna Aceti; Giacomo Faldella
Journal:  Gastroenterol Res Pract       Date:  2013-06-26       Impact factor: 2.260

9.  The Effect of Alginate in Gastroesophageal Reflux in Infants.

Authors:  Silvia Salvatore; Antonio Ripepi; Koen Huysentruyt; Kristel van de Maele; Luana Nosetti; Massimo Agosti; Alessandro Salvatoni; Yvan Vandenplas
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

10.  A Novel In Vitro Model for Determining the Optimum pH and Dose Volume of New Liquid Alginate for Infant Reflux Suppression.

Authors:  Jeanine Fisher; Fiona McLaughlin; Neil Fawkes; Hannah Tipple; Cathal Coyle; Peter W Dettmar
Journal:  Drugs R D       Date:  2021-07-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.